Somewhat Positive Press Coverage Somewhat Unlikely to Affect Inogen (INGN) Stock Price

Media stories about Inogen (NASDAQ:INGN) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Inogen earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news coverage about the medical technology company an impact score of 45.8540068789209 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the media stories that may have impacted Accern Sentiment’s scoring:

Shares of Inogen (NASDAQ:INGN) opened at 103.05 on Monday. Inogen has a 1-year low of $50.24 and a 1-year high of $104.06. The company has a market capitalization of $2.14 billion, a price-to-earnings ratio of 89.45 and a beta of 1.02. The stock’s 50 day moving average price is $94.82 and its 200 day moving average price is $86.16.

Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.10. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The firm had revenue of $64.10 million during the quarter, compared to analysts’ expectations of $59.99 million. During the same quarter in the previous year, the company posted $0.25 EPS. Inogen’s revenue was up 17.4% on a year-over-year basis. Analysts expect that Inogen will post $1.21 EPS for the current year.

Several equities analysts have recently issued reports on INGN shares. Zacks Investment Research upgraded Inogen from a “hold” rating to a “strong-buy” rating and set a $94.00 price target on the stock in a research report on Monday, May 15th. Needham & Company LLC lowered their price target on Inogen from $108.00 to $96.00 and set a “strong-buy” rating on the stock in a research report on Thursday, June 8th. J P Morgan Chase & Co lifted their price target on Inogen to $102.00 and gave the company an “overweight” rating in a research report on Monday, June 26th. Finally, BidaskClub cut Inogen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $91.60.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Inogen (INGN) Stock Price” was reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.themarketsdaily.com/2017/09/11/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-inogen-ingn-stock-price.html.

In other Inogen news, Director Raymond Huggenberger sold 15,300 shares of the company’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $90.88, for a total transaction of $1,390,464.00. Following the completion of the sale, the director now owns 7,808 shares in the company, valued at approximately $709,591.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction on Friday, June 16th. The shares were sold at an average price of $91.54, for a total transaction of $228,850.00. Following the sale, the executive vice president now owns 4,833 shares of the company’s stock, valued at approximately $442,412.82. The disclosure for this sale can be found here. Insiders have sold a total of 59,967 shares of company stock valued at $5,532,015 in the last quarter. Corporate insiders own 5.31% of the company’s stock.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply